Profluent Bio leverages advanced artificial intelligence to revolutionize protein design, moving beyond traditional methods that often rely on inefficient searches in nature or brute-force mutagenesis. Their AI-driven approach decodes the "language of life," allowing for rapid exploration of vast combinatorial spaces to optimize proteins across multiple functional attributes. This paradigm shift enables intentional design rather than accidental discovery, providing unprecedented precision and control in creating bespoke solutions for complex societal challenges.

The company's machine learning models are trained on billions of curated biological sequences, making them adept at designing proteins across various modalities, including enzymes, antibodies, gene editors, and peptides. Profluent Bio's technology not only facilitates the optimization of multiple properties simultaneously but also allows for the exploration of untapped protein spaces, offering unique opportunities beyond existing natural or patented proteins. This innovative approach enables the creation of entirely novel functions through de novo proteins, unlocking infinite potential for engineering unprecedented biological capabilities.

United States

Profluent is an AI-first protein design company. Founded in 2022, we develop deep generative models to design and validate novel, functional proteins to revolutionize biomedicine. Based in Emeryville, CA, we are backed by leading investors including Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures. To learn more about our mission to decode the language of life with AI, visit profluent.bio.

Profluent Bio

Company Details